The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

One in three women will become pregnant after an MS diagnosis, therefore consideration of the maternal-infant dyad is needed.

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and ...

Current clinical trials are investigating treatments like tolebrutinib, fingolimod, ocrelizumab, ublituximab, and fenebrutinib, focusing on safety, efficacy, and specific patient demographics.

For further information on how we select topics for development, please see our page about topic selection ...

The CHIMES study examines the effectiveness of ocrelizumab in Black and Hispanic MS patients. After 24 weeks, the trial showed MRI outcomes comparable to the pivotal phase 3 ocrelizumab OPERA ...

However, as most data is registry-based and previous trials did not directly compare aHSCT with the most efficacious DMTs, Alemtuzumab, Ocrelizumab, Cladribine and Ofatumumab, questions remain over ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...